The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 8th 2018There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.
Watch
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 2nd 2018In order for precision oncology to be fruitful and to be effective, we need interoperability and we need to be able to share patient data, said James Lin Chen, MD, Ohio State University, and chair of ASCO CancerLinQ Oncology Informatics Task Force.
Watch
TCGA Completes Comprehensive Genomic Analysis of 33 Cancer Types
April 10th 2018After a decade of analyzing over 11,000 tumors from 33 types of cancer, the collaboration between the National Cancer Institute and National Human Genome Research Institute has launched the Pan-Cancer Atlas, providing a comprehensive understanding of 3 focus areas: cell-of-origin patterns, oncogenic processes, and signaling pathways.
Read More
Precision Health AI Launches Platform to Deliver Data-Driven Insights in Oncology
March 10th 2018Precision Health AI has launched Eureka Health, a platform that leverages electronic medical record data to provide artificial intelligence through more than 60 pretrained and learning-enhanced modules designed specifically for oncology.
Read More
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 24th 2018Recent study results showed larotrectinib was effective in patients with tropomyosin receptor kinase fusion-positive cancer, regardless of the age of the patient or the tumor type. In addition to implications for the treatment of genetic alterations across tumor types, these study results underscore the importance of molecular profiling of tumors, through which patients were identified for the studies, on ensuring precision medicine is used in practice while simultaneously providing a cost-effective tool.
Read More
Syapse, Roche Team Up to Advance Precision Medicine in Oncology
January 11th 2018Syapse, a leading precision medicine company, and Roche have joined forces to advance precision medicine in oncology. They will work together to bring real-world data to providers, bring oncology into the value-based care era, advance patient-reported outcomes, and optimize clinical trial recruiment.
Read More
New Flow Cytometry-Based Test Approved for Certain Leukemias and Lymphomas
July 3rd 2017A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.
Read More
Precision Oncology: Are Payers on the Right Pathway?
August 4th 2015In oncology, the shift from a "companion diagnostic" to a "companion therapeutic" paradigm is in high gear. While the noise and confusion is leading many payers to avoid coverage, they can benefit by proactively taking steps to integrate precision oncology to better manage quality, access, and cost of cancer care.
Read More